NEW YORK (GenomeWeb) – T2 Biosystems announced today that it has signed a multi-year deal giving Bayer access to its T2 Magnetic Resonance (T2MR) technology platform for use in its R&D efforts in blood coagulation disorders.
Under the terms of the deal, the companies will use the technology to develop tools and evaluate assays for drug discovery and biomarker research in certain Bayer hemostasis-related programs.
Additional terms were not disclosed.
The T2MR technology uses superparamagnetic nanoparticles to measure the reaction of water molecules in the presence of magnetic fields, which is known as a T2 signal. When a binding event occurs inside a sample, the T2 signal changes, making it possible to detect the presence of an analyte.
The technology is the basis for T2's T2Candida sepsis test and its upcoming T2Bacteria bacterial sepsis assay, which is planned for a 2017 launch.